In a sterile lab, a bioreactor hums, not with patient-derived immune cells, but with a master cell line engineered to become a universal starting point for cancer-fighting CAR-Ts. This is the core vision of Link Cell Therapies: to rewire the notoriously complex and costly manufacturing of cell therapies from the ground up. The company has now secured a substantial $60 million seed round to advance its platform, a significant early bet on a technology that could reshape the commercial landscape for these powerful medicines.
Founded by a team of veterans from cell therapy pioneers and synthetic biology startups, Link is tackling the fundamental bottleneck of autologous CAR-T. The current model, which harvests a patient's own T-cells, is bespoke, time-consuming, and exorbitantly expensive. Link's approach involves creating a standardized, renewable cell source that can be differentiated into potent T-cells, aiming for an 'off-the-shelf' product that is available immediately and at a fraction of the cost.
This funding lands squarely within a critical industry trend: the push to solve cell therapy manufacturing. As the first wave of autologous CAR-Ts proved clinically transformative but commercially cumbersome, a second wave of companies is focusing not just on new targets, but on industrializing production. Investors are pouring capital into platforms that promise to streamline, scale, and reduce the vein-to-vein time, seeing manufacturing innovation as the key to unlocking blockbuster potential beyond niche oncology indications.
With this capital, Link Cell Therapies will move its lead program, LCT-101, toward preclinical proof-of-concept. The near-term milestones are clear: demonstrate the functionality, persistence, and safety of its engineered cells in robust animal models. Success there would set the stage for IND-enabling studies and position Link as a serious contender in the race to build the next-generation cell therapy factory.